| Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH (NCT07204041) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-08-01 |
| Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC (NCT06897046) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-07-30 |
| Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC） (NCT06910072) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-07-21 |
| Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC (NCT07186621) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-07-10 |
| Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer (NCT07019337) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-06-30 |
| Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib (NCT07033819) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-06-25 |
| Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors (NCT06926751) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-06-12 |
| Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy (NCT07014202) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-06-11 |
| Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer (NCT07034742) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-06-01 |
| Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer (NCT07040098) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-06-01 |
| A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma (NCT07063888) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-05-16 |
| Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer (NCT06904677) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-05-01 |
| Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer (NCT07166003) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-04-20 |
| Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH (NCT07187193) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-04-12 |
| Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease (NCT07187167) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-04-12 |
| Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer (NCT06858969) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-04-09 |
| Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy (NCT06889402) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-04-01 |
| Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer (NCT06908668) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-03-31 |
| Jianzhong Qushi in Chronic RRI (NCT06837597) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-03-15 |
| A Study On The Prediction of Neoadjuvant Efficacy For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics (NCT07107815) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-03-15 |
| A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis. (NCT06839547) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-03-01 |
| Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis (NCT06839560) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-03-01 |
| Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer (NCT06858956) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-03-01 |
| Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ (NCT06808971) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-02-28 |
| Familial Breast Cancer in China (NCT06833216) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-02-28 |
| Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors. (NCT06928922) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-02-24 |
| QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC (NCT06750861) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-02-15 |
| Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002 (NCT06834438) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-02-15 |
| Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy (NCT06820320) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-02-15 |
| PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer (NCT06842472) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-02-01 |
| Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy (NCT06691594) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-02-01 |
| Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer (NCT06789679) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-01-25 |
| A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults (NCT06761417) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-01-24 |
| A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer (NCT06791161) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-01-19 |
| Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ (NCT06761846) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-01-17 |
| Quantitative Neurofeedback Techniques for Treating Perioperative Cognitive Disorders in Elderly Patients (NCT06752148) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-01-01 |
| Zanubrutinib Combined With G-CVP in Previously Untreated FL (NCT06959732) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-01-01 |
| A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer (NCT07026669) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-01-01 |
| A Study Comparing the Differences Between Young and Non-young Breast Cancer (NCT06793306) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-01-01 |
| Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer (NCT07057102) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-01-01 |
| Multi-Reader Multi-Case Trial Evaluating Computer-Aided Tool for Prognostic Prediction of Colorectal Liver Metastases (NCT07027605) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-01-01 |
| Adaptive Radiotherapy for Genitourinary Cancers (NCT07324798) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-12-01 |
| A Study of ES014 in Subjects With Advanced Solid Tumors (NCT06543056) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-11-25 |
| The Impact of Inflammatory Adhesion on the Prognosis of Colon Cancer Patients (NCT06655285) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-10-24 |
| Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer (NCT06757621) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-10-10 |
| A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer (NCT06776861) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-09-24 |
| Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. (NCT06771609) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-09-10 |
| A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma (NCT06585878) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-09-01 |
| First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma (NCT05188859) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-09-01 |
| Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients (NCT06577961) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-08-31 |
| Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT06509009) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-08-30 |
| A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC (NCT06863831) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-08-22 |
| Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors (NCT06553365) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-08-15 |
| A Study for Dynamic Prediction Model of Breast Cancer Bone Metastases (NCT06544668) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-08-06 |
| GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma (NCT06490341) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-07-20 |
| NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors (NCT06509490) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-07-17 |
| MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer (NCT06498752) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-07-16 |
| Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study (NCT07657494) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-07-11 |
| Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases (NCT06483672) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-07-01 |
| Trilaciclib Prevents Myelosuppression With Chemoradiotherapy (NCT06490081) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-06-26 |
| Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma (NCT06416930) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-06-20 |
| Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy (NCT06490068) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-06-04 |
| Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. (NCT06452433) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-06-01 |
| Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy (NCT06667622) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-29 |
| Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC (NCT06490107) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-24 |
| Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials (NCT06612632) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-24 |
| SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer (NCT06411457) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-16 |
| Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer (NCT06408623) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-15 |
| Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer (NCT06413992) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-10 |
| Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation (NCT06405295) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-06 |
| Effect of (neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients (NCT06405269) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-06 |
| Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer (NCT06419673) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-01 |
| Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis (NCT06389422) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-01 |
| Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer (NCT06405139) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-01 |
| Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer (NCT06421376) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-01 |
| The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study (NCT06958627) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-04-30 |
| NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC (NCT06405490) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-04-17 |
| Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma (NCT06417892) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-04-15 |
| Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors (NCT06346041) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-04-12 |
| Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma (NCT06492629) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-04-03 |
| Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors (NCT06592092) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-04-01 |
| Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer (NCT06430658) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-04-01 |
| Goal-directed Enteral Nutritional Perioperative Management (NCT06510543) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-03-30 |
| Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma (NCT06342167) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-03-14 |
| NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study (NCT06345300) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-03-10 |
| Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC (NCT06371586) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-03-01 |
| Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy (NCT06317558) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-03-01 |
| Longitudinal Study on the Evolution Trend and Influencing Factors of Postoperative Reflux of Esophageal Cancer Based on PEPTEST Technique (NCT06509022) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-03-01 |
| The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer (NCT06287320) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-03-01 |
| Clinical Trial for Advanced or Metastatic Pancreatic Cancer (NCT06255912) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-03-01 |
| Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery (NCT06483698) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-03-01 |
| PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer (NCT06086457) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-02-04 |
| RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations (NCT06185400) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-02-01 |
| Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC (NCT06202014) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-31 |
| Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM (NCT06543069) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-31 |
| Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial (NCT06245824) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-30 |
| Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. (NCT06205472) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-26 |
| Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis (NCT06233981) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-25 |
| Clinical Trial of BT02 in Patients With Advanced Solid Tumors (NCT06404905) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-24 |
| Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC) (NCT06793813) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-23 |